#bictegravir

FDA Approves Gilead’s Single-Tablet HIV Regimen Biktarvy

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

Researchers compared the demographics of participants in randomized controlled trials for antiretrovirals with the global HIV population.

A rundown of POZ’s reporting on the 2020 Conference on Retroviruses and Opportunistic Infections

Researchers are looking for ways to reduce the doses needed for on-demand PrEP and the 30-day duration recommended for PEP.

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.

The single-tablet HIV treatment regimen includes the experimental integrase inhibitor bictegravir and the contents of Descovy.

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Gilead Sciences’ bictegravir-containing combo also has fewer side effects.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

The investigational integrase inhibitor bictegravir appears to have a resistance profile superior to currently available drugs in its class.